TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30859504
Drug: Any of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any of three classes of BP medications
Study: 30860484
Drug: Tablet app
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablet app for the Simplified Gestational Age Score (T-SGAS) used by auxiliary nurse midwives to estimate GA status of newborns.
Study: 30860945
Drug: Neratinib 240
Normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Neratinib 240 mg orally once per day plus capecitabine 750 mg/m²
Study: 30862609
Drug: Palliative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palliative chemotherapy (platinum/pemetrexed)
Study: 30862646
Drug: Isatuximab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isatuximab (5 mg/kg, 10 mg/kg, or 20 mg/kg)
Study: 30862646
Drug: Isatuximab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isatuximab (10 mg/kg)
Study: 30862650
Drug: Bluetooth-enabled insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bluetooth-enabled insulin pen caps
Study: 30863020
Drug: Multicomponent intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multicomponent intervention (educational program for psychiatrists, collaborative care program for patients and relatives, reminder system using a medication reminder application)
Study: 30863141
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment effect of methoxyflurane vs placebo
Study: 30863450
Drug: Single treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single treatment (Control)
Study: 30865002
Drug: Postoperative administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative administration of opioids
Study: 30865223
Drug: Molecular-based recommended
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Molecular-based recommended therapies (MBRT)
Study: 30865367
Drug: Heart failure
Normalized name: INVESTIGATIONAL CONGESTIVE HEART FAILURE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heart failure medications (including ACE-Is/ARBs, β-blockers, MRAs, digoxin, ivabradine, diuretics)
Study: 30866657
Drug: nHDL <100
Approvals — FDA: no, EMA: no, PMDA: no
Description: nHDL <100 mg/dL
Study: 30866657
Drug: nHDL 100-129
Approvals — FDA: no, EMA: no, PMDA: no
Description: nHDL 100-129 mg/dL
Study: 30866657
Drug: nHDL ≥130
Approvals — FDA: no, EMA: no, PMDA: no
Description: nHDL ≥130 mg/dL
Study: 30866657
Drug: LDL <70
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL <70 mg/dL
Study: 30866657
Drug: LDL 70-99
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL 70-99 mg/dL
Study: 30866657
Drug: LDL ≥100
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL ≥100 mg/dL
Study: 30866657
Drug: Triglyceride <84
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triglyceride <84 mg/dL
Study: 30866657
Drug: Triglyceride 84-149
Normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triglyceride 84-149 mg/dL
Study: 30866657
Drug: Triglyceride ≥150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triglyceride ≥150 mg/dL
Study: 30866994
Drug: Coagulated blood
Normalized name: blood coagulation factor XIV
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coagulated blood from the patient as an alternative for ultrasound gel
Study: 30867935
Drug: Safe Childbirth
Normalized name: Safe-Guard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safe Childbirth Checklist (SCC) program implemented in 19 intervention facilities with monthly supportive supervision and supply of drugs and equipment.
Study: 30868475
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care plus PEMF therapy
Study: 30868550
Drug: Tumor Necrosis
Normalized name: Tumor necrosis factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumor Necrosis Factor Inhibitors (TNFis)
Study: 30869114
Drug: Early childhood
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early childhood protein intake (mean 58.3 g/d)
Study: 30869127
Drug: artemether-lumefantrine treatment
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: artemether-lumefantrine treatment
Study: 30871493
Drug: Nivolumab (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (240 mg Q2W) followed by nivolumab (240 mg Q2W) and ipilimumab (1 mg/kg Q6W) after a 3-cycle run-in phase.
Study: 30871493
Drug: Nivolumab (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (240 mg Q2W) only for patients not escalated to ipilimumab.
Study: 30872388
Drug: Osimertinib (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osimertinib (80 mg oral dose) in patients with mild hepatic impairment
Study: 30872388
Drug: Osimertinib (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osimertinib (80 mg oral dose) in patients with moderate hepatic impairment
Study: 30872388
Drug: Osimertinib (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osimertinib (80 mg oral dose) in patients with normal hepatic function
Study: 30873290
Drug: Milk powder
Normalized name: Milk powder
DrugBank: Skim milk (DB15546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk powder supplemented with calcium and vitamin D and periodontal therapy (PT)
Study: 30873290
Drug: Conventional periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional periodontal treatment and consumption of milk fortified with calcium-vitamin D
Study: 30873623
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K antagonists (VKA) ± antiplatelet (AP) therapy
Study: 30873623
Drug: Non-VKA oral
Normalized name: Tavist Non-Sedating Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-VKA oral anticoagulant (NOAC) ± AP
Study: 30875094
Drug: Fexofenadine 120
Normalized name: fexofenadine hydrochloride 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine 120 mg + Osimertinib 80 mg single dose on days 1 and 39 and Osimertinib 80 mg once daily from days 4 to 41
Study: 30875094
Drug: Fexofenadine 120
Normalized name: fexofenadine hydrochloride 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine 120 mg + Osimertinib 80 mg at steady state
Study: 30876442
Drug: Simultaneous integrated
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous integrated boost (SIB) technique with elective nodal irradiation (ENI) and dual-drug chemotherapy (paclitaxel and nedaplatin) at Maximum Tolerated Dose (MTD) of 59.92Gy/2.14Gy/28f
Study: 30876442
Drug: Simultaneous integrated
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous integrated boost (SIB) technique with elective nodal irradiation (ENI) and dual-drug chemotherapy (paclitaxel and nedaplatin)
Study: 30876442
Drug: Simultaneous integrated
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous integrated boost (SIB) technique with elective nodal irradiation (ENI) and dual-drug chemotherapy
Study: 30876444
Drug: dIMRT (dynamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: dIMRT (dynamic intensity-modulated radiation therapy)
Study: 30876444
Drug: VMAT (volumetric-modulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: VMAT (volumetric-modulated arc therapy)
Study: 30877202
Drug: Tocilizumab (TCZ)
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab (TCZ) therapy, administered via injections at weeks 0, 4, and 8
Study: 30877569
Drug: Olaparib 300
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 300 mg single-dose
Study: 30877569
Drug: Olaparib 200
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 200 mg twice daily
Study: 30879979
Drug: qHPV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: qHPV vaccine (three doses on Day 1, Month 2, Month 6)
Study: 30880554
Drug: Medical nutrition
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical nutrition therapy program
Study: 30881452
Drug: Intramuscular neridronate
Normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular neridronate (25 mg IM once a month for 6 years)
Study: 30881909
Drug: Fractionated-dose spinal
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractionated-dose spinal anesthesia injection
Study: 30881909
Drug: Single-dose spinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose spinal anesthesia injection
Study: 30883662
Drug: AdV-tk at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: AdV-tk at doses of 1 × 10^11 and 3 × 10^11 vector particles (vp) injected into the tumor bed followed by 14 days of valacyclovir.
Study: 30883662
Drug: AdV-tk at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: AdV-tk at dose level 2.
Study: 30883668
Drug: Post-operative pain
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-operative pain treatment (various analgesic treatments used, including morphine)
Study: 30883668
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine consumption
Study: 30885222
Drug: Increased sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased sodium excretion and plasma sodium
Study: 30885327
Drug: Atezolizumab plus
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab plus chemotherapy (carboplatin and etoposide)
Study: 30885354
Drug: Radical consolidative
Normalized name: Campsis radicans flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radical consolidative treatment (RCT)
Study: 30886964
Drug: Ambrisentan 5
Normalized name: ambrisentan 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambrisentan 5 mg/day for 12 months
Study: 30886990
Drug: Modified Pilates
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Pilates exercises, treated twice a week for eight weeks.
Study: 30886990
Drug: Aerobic exercises
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerobic exercises on treadmills or stationary bikes, treated twice a week for eight weeks.
Study: 30887180
Drug: Olaparib 300
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 300 mg (twice daily) as monotherapy
Study: 30887180
Drug: Olaparib 100
Normalized name: olaparib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib 100 mg (twice daily) as monotherapy
Study: 30887180
Drug: Olaparib 100
Normalized name: olaparib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib 100 mg (twice daily) in combination with paclitaxel (80 mg/m weekly)
Study: 30887180
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (Olaparib + Paclitaxel)
Study: 30887876
Drug: Guselkumab administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guselkumab administered with a novel patient-controlled injector (One-Press)
Study: 30888111
Drug: Predictive model
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Predictive model for risk of variceal bleeding comprising of grade 2-3 esophageal varices, red spots, and fibrinogen level <150 mg/dL
Study: 30889492
Drug: Trifluridine/tipiracil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trifluridine/tipiracil at recommended dose (RD) of 35 mg/m² in combination with oxaliplatin
Study: 30890162
Drug: Remotely supervised
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remotely supervised transcranial direct current stimulation (RS-tDCS) administered daily (Monday - Friday) for a total of sixty sessions, 20 minutes of 2.5 mA direct current targeting the cerebellum, paired with cognitive training and physical exercises.
Study: 30890544
Drug: Plerixafor (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plerixafor (240 µg/kg)
Study: 30890548
Drug: Low-intensity pulsed
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity pulsed ultrasound (LIPU) using SonoCloud-1 device, activated monthly before intravenous carboplatin chemotherapy.
Study: 30890548
Drug: Low-intensity pulsed
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity pulsed ultrasound (LIPU) using SonoCloud-1 device before carboplatin chemotherapy.
Study: 30890600
Drug: Fludarabine, cyclophosphamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine, cyclophosphamide, and rituximab (FCR) induction followed by 36 months of rituximab maintenance therapy
Study: 30891607
Drug: Intradermal delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal delivery of INO-4201
Study: 30891607
Drug: Intramuscular delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular delivery of INO-4201
Study: 30891607
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of INO-4201 and INO-4202 with interleukin-12
Study: 30891607
Drug: Intradermal delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal delivery of INO-4202
Study: 30891607
Drug: Intramuscular delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular delivery of INO-4202
Study: 30892988
Drug: Venetoclax 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax 600 mg per day orally in 28-day cycles plus low-dose cytarabine (LDAC) 20 mg/m²
Study: 30895237
Drug: Corifollitropin alfa
Normalized name: corifollitropin alfa
DrugBank: Corifollitropin alfa (DB09066)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Corifollitropin alfa 150 μg
Study: 30895244
Drug: 0.5 mL
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mL insemination volume
Study: 30895244
Drug: 0.2 mL
Normalized name: isopropyl alcohol 0.2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mL insemination volume
Study: 30896447
Drug: Cyclophosphamide (Cy)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (Cy) 1.5 g/m2 + CART-BCMA cells (1-5 x 10^7 cells)
Study: 30896447
Drug: Cyclophosphamide (Cy)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (Cy) 1.5 g/m2 + CART-BCMA cells (1-5 x 10^8 cells)
Study: 30896447
Drug: CART-BCMA infusions
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CART-BCMA infusions with or without lymphodepleting chemotherapy
Study: 30898821
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (HCQ) 400 mg daily oral treatment, initiated before conception and stopped at 10 weeks' gestation.
Study: 30898821
Drug: Placebo, daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, daily oral treatment, initiated before conception and stopped at 10 weeks' gestation.
Study: 30899297
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of subcutaneous collateral vessel of the chest/abdominal wall
Study: 30900412
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose challenge test results
Study: 30900412
Drug: Time interaction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time interaction for insulin
Study: 30901867
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 4 mg ondansetron and 4 mg dexamethasone
Study: 30902361
Drug: Intranasal hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal hydromorphone (0.03 mg/kg initial dose, additional 0.015 mg/kg if needed)
Study: 30902361
Drug: Intranasal hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal hydromorphone
Study: 30902915
Drug: Paclitaxel (chemotherapy)
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel (chemotherapy)
Study: 30903275
Drug: Pazopanib (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib (800 mg orally QD)
Study: 30903661
Drug: Plans to
Normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Plans to keep pills
Study: 30903661
Drug: Plans to
Normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Plans to dispose of pills
Study: 30904021
Drug: myo-inositol (1.75 g/day),
Approvals — FDA: no, EMA: no, PMDA: no
Description: myo-inositol (1.75 g/day), D-chiro-inositol (0.25 g/day), glucomannan (4 g/day) for 3 months
Study: 30904854
Drug: Internet-based, therapist-guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based, therapist-guided cognitive-behavioural therapy (CBT) for BDD, 12-week treatment consisting of eight treatment modules.
Study: 30904859
Drug: Low-dose chest
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose chest CT lung cancer screening
Study: 30904869
Drug: Short-course radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course radiotherapy (SCRT) at dose levels of 6Gy×5F, 7Gy×5F, 8Gy×5F followed by four cycles of modified FOLFOX6 (mFOLFOX6) chemotherapy as neoadjuvant therapy.
Study: 30904980
Drug: Pralatrexate IV
Normalized name: Pralatrexate
DrugBank: Pralatrexate (DB06813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pralatrexate IV 30 mg/m²
Study: 30905354
Drug: RFA for
Normalized name: Rfaudraksha resin
DrugBank: Acacia (DB10451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RFA for treatment of flat USLs
Study: 30906694
Drug: Gambling intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gambling intervention only (G only)
Study: 30906694
Drug: Gambling intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gambling intervention with mental health intervention (G + MH)
Study: 30907259
Drug: EndoAnchor implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: EndoAnchor implants with good penetration
Study: 30907453
Drug: Anti-staphylococcal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-staphylococcal treatment
Study: 30908927
Drug: Combined Forced
Normalized name: benzalkonium chloride Topical Solution [Clean Force]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Forced Expiratory Volume in 1 Second and Forced Vital Capacity Bronchodilator Response
Study: 30909832
Drug: Ranolazine 500
Normalized name: ranolazine 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranolazine 500 mg
Study: 30909832
Drug: Ranolazine 1000
Normalized name: ranolazine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranolazine 1000 mg
Study: 30910221
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone treatment (mean dose: 0.4mg/kg/week at month 0, M12, M24; 0.3mg/kg/week at M36)
Study: 30910221
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone treatment
Study: 30910890
Drug: Weight-based dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-based dosing guidelines for antituberculosis drugs
Study: 30910890
Drug: Dose increment
Normalized name: Urinary concrement solvents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose increment of one fixed-dose combination (FDC) tablet for weight bands of 30 to 37 and 38 to 54 kg
Study: 30910890
Drug: Different formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different formulations of rifampin and isoniazid
Study: 30910890
Drug: Current dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current dosing guidelines
Study: 30910890
Drug: Adding one
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adding one FDC tablet to current weight band-based dosing
Study: 30910891
Drug: Intravenous rifampin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous rifampin, 8 mg/kg for <14 days PNA, 15 mg/kg for ≥14 days PNA, administered once daily
Study: 30910892
Drug: Intravenous and
Normalized name: immune globulin intravenous and subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous and oral fluconazole
Study: 30911064
Drug: Prenatal acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenatal acetaminophen use (any use)
Study: 30911064
Drug: No prenatal
Normalized name: Vitafol-Nano Prenatal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: No prenatal acetaminophen use
Study: 30911405
Drug: Remote ischemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote ischemic conditioning (RIC) administered by EMS paramedics using the autoRIC® device, 4 cycles of 5-min inflation and 5-min deflation of an upper arm cuff
Study: 30911655
Drug: Adjuvant PIPAC-directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant PIPAC-directed therapy with oxaliplatin (92 mg/m2)
Study: 30911655
Drug: Adjuvant PIPAC-directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant PIPAC-directed therapy
Study: 30911655
Drug: PIPAC-directed therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIPAC-directed therapy
Study: 30911657
Drug: ABP (Abraxane™)
Normalized name: ABPC
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ABP (Abraxane™) administered via pressurized intraperitoneal aerosol chemotherapy (PIPAC) at escalating doses from 35 to 140 mg/m², with three treatments at 4-week intervals.
Study: 30911656
Drug: Pressurized IntraPeritoneal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) using doxorubicin (1.5 mg/m²) in series of three procedures